Authors
Felicia Tejawinata, Malena Jhonson, Pingfu Fu, Ankit Mangla
Published in
American journal of clinical oncology. Aug 05, 2026. Epub Aug 05, 2026.
Abstract
Tenosynovial giant cell tumor (TGCT) is a rare mesenchymal tumor driven by overexpression of colony-stimulating factor 1 (CSF1) in a few neoplastic synovial cells. Although known to be an ultrarare tumor, the racial distribution of TGCT is understudied.
We queried the Surveillance, Epidemiology, and End Results (SEER) database versions 8 (1975 to 2021) and 22 (2000 to 2021) for patients with TGCT. Patients with TGCT were identified using ICD-O-3 codes 9252/0 (benign TGCT) and 9252/3 (malignant TGCT). Descriptive statistics for racial distribution, relative survival, and other parameters were conducted using the χ2 test.
A total of 78 patients with TGCT were identified in the SEER 22 database. Racial distribution was significantly in favor of White patients (n=51) versus Black patients (n=5) and Asian or Pacific Islander (AAPI) patients (n=5) (P<0.001). Twenty-two additional cases were identified in the SEER 8 database, with a higher preponderance among White patients (n=19) compared with Black patients (n=2) and AAPI patients (n=1) (P<0.001). In the SEER 22 and 8 data sets, the relative survival at 12 months was highest for White patients (98.5% and 90%, respectively), followed by AAPI patients (87.6% in both data sets), and then by Black patients (80% and 80.7%, respectively).
TGCT has a significantly higher incidence in White patients compared with non-White patients. Relative survival appears favorable overall but may be better among White patients than among non-White patients.
PMID:
42561111
Bibliographic data and abstract were imported from PubMed on 07 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0